Who Owns Lash Group?

Lash Group operates under Cencora's corporate sustainability framework. Cencora's sustainability strategy focuses on improving healthcare access, reducing environmental impact, and maintaining ethical business practices across its global operations. The company reports on environmental, social, and governance metrics in its annual sustainability reports.

Lash Group's core mission centers on improving healthcare access and equity for patients facing financial barriers to medication access. The company's patient support programs help reduce healthcare disparities by ensuring patients can access essential medications regardless of their financial circumstances or insurance coverage limitations. This social mission is a fundamental part of Lash Group's business model.

As a company handling sensitive patient information, Lash Group maintains strict HIPAA compliance measures and privacy protection programs. The company implements comprehensive security standards for handling patient health information while providing personalized support services. Employee training programs ensure staff understand healthcare regulations, patient privacy requirements, and ethical patient support practices.

Cencora has committed to environmental sustainability targets, including reducing greenhouse gas emissions across its operations and supply chain. However, as a services company, Lash Group's direct environmental impact is limited compared to Cencora's distribution and logistics operations. Cruelty-free, vegan, organic, and fair trade certifications do not apply to pharmaceutical services companies.

Lash Group itself has not been subject to product recalls or direct regulatory enforcement actions as of July 2025. However, parent company Cencora has faced significant legal and regulatory challenges related to its role in the U.S. opioid epidemic, which has affected the company's reputation and financial position.

Cencora (as AmerisourceBergen) was one of three major pharmaceutical distributors that agreed in 2022 to pay $21 billion over 18 years to resolve claims by state and local governments that they failed to properly monitor and report suspicious opioid shipments. Cencora's share of this settlement was approximately $6.4 billion over 18 years. This settlement resolved the majority of opioid-related lawsuits filed by state and local governments against the company.

In November 2024, a jury in the Circuit Court for Baltimore found McKesson and Cencora liable for fueling the opioid epidemic in Baltimore. The jury awarded $266 million in compensatory damages, with Cencora responsible for $74 million. Baltimore had opted out of the national opioid settlements in hopes of winning more money through its own lawsuit. Additional damages phases were expected.

In August 2024, Cencora, McKesson, and Cardinal Health agreed to pay $300 million to settle claims by health insurers and benefit plans that they helped fuel the opioid epidemic. This settlement resolved a class action lawsuit filed by third-party payers including union funds.

In 2025, Cencora's directors agreed to a $111.3 million settlement to resolve claims by pension funds that they ignored years of red flags about the drug distributor's handling of opioid painkillers. The lawsuit, filed in Delaware Chancery Court, accused Cencora's leadership of failing to set up required systems to monitor suspicious opioid sales. The directors denied the claims but agreed to settle to avoid further litigation costs.

In October 2025, a federal appeals court reversed a 2022 ruling that had found McKesson, Cardinal Health, and Cencora not legally responsible for the opioid epidemic in Cabell County, West Virginia, and Huntington. The case, involving $2.5 billion in claims, was sent back for retrial.

These opioid-related legal issues have affected Cencora's reputation and financial position, though the company has absorbed the costs through its strong revenue base. Lash Group, as a patient support services subsidiary, is not directly implicated in the opioid distribution practices that led to these settlements.